Thu, Jul 10, 2014, 7:23 AM EDT - U.S. Markets open in 2 hrs 7 mins

Recent

% | $
Quotes you view appear here for quick access.

InvenSense, Inc. Message Board

matmasr2008 2 posts  |  Last Activity: Apr 11, 2014 3:41 PM Member since: Jun 16, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    The facts about Affymax Patents

    by matmasr2008 Apr 11, 2014 12:22 PM
    matmasr2008 matmasr2008 Apr 11, 2014 3:41 PM Flag

    Well, ask yourself this question, who benefits the most from an AFFY stock value drop ? Two entities come in mind; those who shorted the stock and those who will own the remnants of Affymax, i.e its Intellectual property. Imagine you are going to buy a used car, you know that it is valuable, but you note to the seller that it has a list of all these flaws, trying to persuade the seller to lower the sell value, and even appearing to be stepping in and doing him a favor by even taking this car ... same logic in my opinion .. but who knows ...

  • So many posts about Takeda dropping patent protection of O which seems to me to be a little strange. Here are the facts.

    A Patent does not give a right to make or use or sell an invention. Rather, a patent provides the right to exclude others from making, using, selling, offering for sale, or importing the patented invention for the term of the patent, which is usually 20 years from the filing date subject to the payment of maintenance fees.
    In the United States, the maintenance fees on utility patents are due 3½, 7½ and 11½ years after grant of the patent. The Patent Maintenance Fees are as follows:
    Due at 3.5 years 1,600.00
    Due at 7.5 years 3,600.00
    Due at 11.5 years 7,400.00
    A patent search of Affymax shows that the company has 111 patents that names Affymax as assignee. So, at 3.5 years, Takeda will have to pay $1,600 x 111 = $177,600 to continue to protect the patents. At 7.5 years about $400,000 and at 11.5 years about $ 850,000. This is assuming all of these fall within the same window and all of these are worth protecting. If these factors are taken in, say only a few patents are due for renewal every year over the next year or two I would say a quick swag would be annual maintenance fees of no more than $150,000.

    It’s hard to believe that Takeda would not make that investment to protect a billion dollar drug even if they don't believe its coming back. I say this is basher talk. The hope is still there that the drug will be reintroduced.

    Sentiment: Hold

INVN
23.59+1.11(+4.94%)Jul 9 4:03 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Gigamon Inc.
NYSEWed, Jul 9, 2014 4:04 PM EDT
Alaska Air Group, Inc.
NYSEWed, Jul 9, 2014 4:02 PM EDT